Ascletis Pharma Inc. (01672) disclosed a repurchase of 200,000 ordinary shares on 23 October 2025, representing approximately 0.0201% of its issued shares (excluding treasury shares) before the transaction. According to the announcement, the repurchased shares were added to treasury, bringing the total number of treasury shares to 6,484,210, while the number of issued shares (excluding treasury shares) stood at 992,474,320 as of 23 October 2025, with an unchanged overall total of 998,958,530.

The filing also revealed earlier share repurchases designated for cancellation, totaling 960,000 shares from April to October 2025. However, these had not been canceled as of the reporting date. In addition, the repurchase report indicated that 200,000 shares were bought on the Exchange on 23 October 2025 at prices ranging between HKD 8.86 and HKD 9.2, resulting in an aggregate consideration of HKD 1,802,960.

Under the repurchase mandate granted on 22 May 2025, Ascletis Pharma Inc. was authorized to repurchase up to 96,284,628 shares. As of the date of the announcement, the issuer had bought back 860,000 shares under this mandate, equivalent to roughly 0.0892% of the number of issued shares (excluding treasury shares) at the time the mandate was granted.